Rafael Holdings, Inc. (RFL)
NYSE: RFL · Real-Time Price · USD
1.060
-0.010 (-0.93%)
Nov 5, 2026, 11:17 AM EST - Market open
Rafael Holdings Revenue
In the fiscal year ending July 31, 2026, Rafael Holdings had annual revenue of $874.00K, down -4.69%. Rafael Holdings had revenue of $244.00K in the quarter ending July 31, 2026, a decrease of -30.29%. That makes Rafael Holdings the 43,823rd largest company in the world by revenue and 6,151st in the United States.
Revenue (ttm)
$874.00K
Revenue Growth
-4.69%
P/S Ratio
63.88
Revenue / Employee
$38,000
Employees
23
Market Cap
55.31M
Revenue by Segment
Fiscal year ended Jul 31, 2025 See the full Rafael Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2026 | 874.00K | -43.00K | -4.69% |
| Jul 31, 2025 | 917.00K | 280.00K | 43.96% |
| Jul 31, 2024 | 637.00K | - | - |
| Jul 31, 2023 | - | - | - |
| Jul 31, 2022 | 410.00K | -392.00K | -48.88% |
| Jul 31, 2021 | 802.00K | -4.11M | -83.67% |
| Jul 31, 2020 | 4.91M | -21.00K | -0.43% |
| Jul 31, 2019 | 4.93M | 560.00K | 12.81% |
| Jul 31, 2018 | 4.37M | -1.25M | -22.20% |
| Jul 31, 2017 | 5.62M | 29.00K | 0.52% |
| Jul 31, 2016 | 5.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Douglas Elliman | 1.01B |
| Altisource Portfolio Solutions | 192.51M |
| Star Holdings | 98.27M |
| New England Realty Associates Limited Partnership | 97.23M |
| Fangdd Network Group | 39.33M |
| American Strategic Investment Co. | 33.41M |
| J.W. Mays | 21.09M |
| Linkhome Holdings | 20.80M |
RFL News
- 2 days ago - Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - GlobeNewsWire
- 7 days ago - Rafael Holdings Earnings release: Q4 2026 - Filings
- 7 days ago - Rafael Holdings Annual report: Q4 2026 - Filings
- 7 days ago - Rafael Holdings submits New Drug Application to FDA for remibetadex - TheFly
- 7 days ago - Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 5 weeks ago - Rafael Holdings Transcript: Study result - Transcripts
- 5 weeks ago - Rafael Holdings Press release: Study result - Filings